Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Merck & Co Inc
Recent news which mentions Merck & Co Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
June 03, 2024
Tags
Health care industry
Companies
Business News
From
CNBC.com News
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
May 30, 2024
Tags
Johnson & Johnson
Healthy Returns
Health care industry
From
CNBC.com News
5 things to know before the stock market opens Wednesday
May 29, 2024
Tags
T/Mobile US Inc
Markets
Business
From
CNBC.com News
Cramer says these 10 stocks helped the Dow briefly crack 40,000
May 16, 2024
Tags
Stock markets
Investment strategy
Caterpillar Inc
From
CNBC.com News
Cramer explains how to maintain a 'balanced' portfolio as the economy slows
May 07, 2024
Tags
Mad Money
Business News
Pfizer Inc
From
CNBC.com News
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
April 25, 2024
Tags
US: News
Business
Earnings
From
CNBC.com News
5 things to know before the stock market opens Monday
April 22, 2024
Tags
General Electric Co
Comcast Corp
NVIDIA Corp
From
CNBC.com News
Cramer’s week ahead: Earnings from Tesla, Merck and Big Tech
April 19, 2024
Tags
Chevron Corp
Alphabet Inc
Spotify Technology SA
From
CNBC.com News
FDA approves Merck's drug for rare, deadly lung condition
March 26, 2024
Tags
Science
Biotech and Pharmaceuticals
Biotechnology
From
CNBC.com News
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
March 19, 2024
Tags
Alphabet Inc
Healthy Returns
Health care industry
From
CNBC.com News
Healthy Returns: What’s next in the legal fight over Medicare drug price negotiations
March 13, 2024
Tags
Merck & Co Inc
AstraZeneca PLC
Johnson & Johnson
From
CNBC.com News
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
March 10, 2024
Tags
Companies
Merck & Co Inc
Business News
From
CNBC.com News
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
February 23, 2024
Tags
Science
Pharmaceuticals
Health & Science
From
CNBC.com News
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
February 22, 2024
Tags
US: News
Business
Earnings
From
CNBC.com News
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
February 13, 2024
Tags
Health care industry
Bristol/Myers Squibb Co
Johnson & Johnson
From
CNBC.com News
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
February 08, 2024
Tags
Biotechnology
Biotech and Pharmaceuticals
Congress
From
CNBC.com News
Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch
February 02, 2024
Tags
Energy
Health & Science
Meta Platforms Inc
From
CNBC.com News
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
February 01, 2024
Tags
Breaking news
Merck & Co Inc
Business News
From
CNBC.com News
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
January 30, 2024
Tags
Merck & Co Inc
Bristol/Myers Squibb Co
Healthy Returns
From
CNBC.com News
5 things to know before the stock market opens Monday
January 29, 2024
Tags
Peloton Interactive Inc
Investment strategy
Apple Inc
From
CNBC.com News
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
January 28, 2024
Tags
Breaking news
Amgen Inc
Moderna Inc
From
CNBC.com News
Cramer's week ahead: Fed meeting, labor report, Big Tech earnings
January 26, 2024
Tags
Stock markets
Investment strategy
Chevron Corp
From
CNBC.com News
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
January 26, 2024
Tags
Johnson & Johnson
Bristol/Myers Squibb Co
Health care industry
From
CNBC.com News
Dow goes from 37,000 to 38,000 in just 40 days. A history of the Dow and big round numbers
January 23, 2024
Tags
Markets
Travelers Companies Inc
Merck & Co Inc
From
CNBC.com News
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
January 14, 2024
Tags
Pharmaceuticals
GSK plc
Health & Science
From
CNBC.com News
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
January 08, 2024
Tags
US: News
Business
Breaking news
From
CNBC.com News
Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
January 02, 2024
Tags
Moderna Inc
Merck & Co Inc
Breaking news
From
CNBC.com News
Biden administration's Medicare drug price negotiations will face major tests in 2024
December 28, 2023
Tags
Companies
Novo Nordisk A/S
Business News
From
CNBC.com News
Jim Cramer explains how FTC chair Lina Khan is hurting investor portfolios
December 18, 2023
Tags
Mad Money
Hershey Co
Rite Aid Corp
From
CNBC.com News
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
December 14, 2023
Tags
Pharmaceuticals
US: News
Health & Science
From
CNBC.com News
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.